Academic Seminars

“Moving basic research on RGS proteins into clinical benefits against the opioid crisis” GSBS Guest Speaker David Siderovski, PhD
November 8, 2019
 

David Siderovski, PhD, will be the GSBS guest speaker on November 14, 2019. He will be presenting “Moving basic research on RGS proteins into clinical benefits against the opioid crisis”.

Seminar location: CBH-230; November 14, 2019 beginning at 10 a.m.

Dr. David Siderovski, Ph.D., accepted the E.J. Van Liere Endowed Medicine Professorship and Chairmanship of West Virginia University’s Department of Physiology and Pharmacology in July of 2012. Siderovski graduated with a Bachelor of Science (Honors) degree in 1989 from Queen’s University in Kingston, Ontario, Canada, majoring in biochemistry. Siderovski began his Ph.D. training at the University of Toronto in May 1989; during his fifth year of Ph.D. training, he also began full-time work as a Research Scientist of the Amgen Research Institute.

He left Amgen in December 1998, after having contributed to three corporate patents, to join the faculty at the University of North Carolina at Chapel Hill, first as a tenure-track Assistant Professor of Pharmacology and rising through the ranks to end in 2012 as a tenured Professor and Director of Chemical Biology, as well as the Thomas J. Dark Basic Science Research Director of the UNC Medical Scientist Training Program for six years. His foundational work at UNC on a new class of GPCR signaling regulators – the RGS proteins – has been published in over 160 works, cited over 21,000 times, and received the John J. Abel Award in 2004 from the American Society for Pharmacology and Experimental Therapeutics.

Now at WVU, Siderovski served for six years as the Chair of the Department of Physiology and Pharmacology (recently merged then de-merged with the Department of Neuroscience), as well as Director of the WVU Medical Scientist Training Program. His trainees have become established as tenure-track and tenured faculty at multiple higher education institutions across North America, including the Universities of New Mexico, Wisconsin-Madison, North Carolina at Chapel Hill, and Ottawa, Canada, as well as in industry placements (e.g., two senior scientists each at Eli Lilly & Co. (Indianapolis) for a decade).